ROBERT HARRIS: Open Payments
NPI 1508047085 · MILTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,183 in 94 payments from 15 companies in 2025. Trend: 2023 $1,801 · 2024 $2,445 · 2025 $2,183
Food & beverage: $2,183
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $780 |
| Novo Nordisk Inc | 9 | $223 |
| Novartis Pharmaceuticals Corporation | 10 | $208 |
| AstraZeneca Pharmaceuticals LP | 7 | $180 |
| Lilly USA, LLC | 8 | $179 |
| PFIZER INC. | 8 | $174 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $134 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Exact Sciences Corporation | 2 | $47 |
| Merck Sharp & Dohme LLC | 2 | $47 |
Products named: JARDIANCE, CREON, Wegovy, LEQVIO, LINZESS, FARXIGA, UBRELVY, QULIPTA.
Industry payments across MA — which companies pay providers there.
